• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    All News #Library
    Biotech

    Takeda`s Next-Gen Immune Drug Matches Approved Rival in Study

    REUTERS

    Protagonist Exercises U.S. Opt-Out Right for Rusfertide

    PHARMIWEB

    Denali Regains Full Rights to Investigational Therapy DNL593

    GLOBENEWSWIRE

    Axsome Acquires PDE10A Inhibitor Balipodect for Schizophrenia

    GLOBENEWSWIRE

    Takeda Zasocitinib Shows Durable Skin Clearance In Psoriasis

    BUSINESSWIRE

    Takeda Clears Path To FDA With Phase 3 Data On $4B Psoriasis Bet

    FIERCE BIOTECH

    Protagonist Prefers $400M From Takeda Over Rusfertide US Profits

    FIERCE BIOTECH

    Does Vaxart Hold The Key To The Elusive Norovirus Vaccine?

    BIOSPACE

    FDA Accepts Takeda`s Oveporexton NDA For Priority Review

    BUSINESSWIRE

    Takeda Inks $1.7B AI Discovery Deal With Iambic Therapeutics

    FIERCE BIOTECH

    Iambic Collaborates With Takeda On Ai-Driven Small Molecule

    BUSINESSWIRE

    Takeda Launches Low-IgA GAMMAGARD LIQUID in U.S

    BUSINESSWIRE

    JPM26, Day 1: Updates From Lilly, Takeda, Novartis And Sofinnova

    FIERCE BIOTECH

    Takeda, Protagonist Submit Rusfertide (NDA) For Polycythemia Vera

    BUSINESSWIRE

    Takeda`s AI-crafted Psoriasis Pill Succeeds in Late-Stage Studies

    REUTERS

    Takeda Looks To 2026 FDA Filing For Sotyktu Rival Zasocitinib

    FIERCE BIOTECH

    BaseLaunch Welcomes Takeda As Pharma Partner In Biotech Venture

    PR NEWSWIRE

    Kamada Halts Phase 3 Inhaled AAT Trial, Retains 2025 Guidance

    GLOBENEWSWIRE

    Protagonist, Takeda Present Rusfertide PV Data at ASH 2025

    BUSINESSWIRE

    Takeda Seals $1.2 Billion Oncology Deal With Innovent Biologics

    PRESS RELEASE

    Neurocrine-Takeda Psychiatry Pact Suffers Another Phase 2 Fail

    FIERCE BIOTECH

    Takeda Reveals Mezagitamab TAK-079 Maintains Kidney Function

    BUSINESSWIRE

    Ph 3 Data Show Takeda Dengue Vaccine Gives 7 Years Protection

    BUSINESSWIRE

    HyHub and HyHub Duo Launch in U.S. for Easier HYQVIA Prep

    BUSINESSWIRE

    China`s Innovent Signs $11.4 B Cancer Therapy Deal with Takeda

    REUTERS

    Nabla Bio, Japan`s Takeda Expand AI Drug Design Partnership

    REUTERS

    Takeda Exits Cell Therapy Research

    INDPHARMAPOST

    Bms, Takeda Join Peers In Push To Improve AI By Pooling Data

    FIERCE BIOTECH

    Takeda Ends All Cell Therapy Work As Part Of Strategic Shift

    FIERCE BIOTECH

    Takeda, Alkermes Reveal Narcolepsy Rivals Amid Intensifying Race

    FIERCE BIOTECH

    FDA Expansion Approves of Vonvendi for Von Willebrand Disease

    BUSINESSWIRE

    Keros Therapeutics Doses First Patient in Phase 3 RENEW trial

    GLOBENEWSWIRE

    Takeda`s Gammagard Liquid ERC Approved by U.S. Fda

    BUSINESSWIRE

    EC Approves Adcetris for Treating Adult Hodgkin Lymphoma

    BUSINESSWIRE

    Novavax, Takeda Improve Nuvaxovid Collaboration Terms in Japan

    PR NEWSWIRE

    BioLife Plasma Services Introduces Fresenius Kabi Nomogram in U.S

    BUSINESSWIRE

    Takeda to launch dengue vaccine in India with Biological E

    ECONOMICTIMES

    Belief BioMed & Takeda announce China`s 1st hemophilia B gene therapy

    PR NEWSWIRE

    BioInvent gets payment as Takeda advances mezagitamab to Phase 3

    ACCESSWIRE

    Takeda`s oncology execs sharpen focus after restructuring

    FIERCE BIOTECH

    Takeda Pumps $770M Into BridGene Pact to Hit Targets

    BIOSPACE

    EMA approves Takhzyro for HAE patients 12+ year & above

    PR NEWSWIRE

    Keros, Takeda Partner To Advance Elritercept With Global License

    GLOBENEWSWIRE

    Takeda Announces Approval of HYQVIA in Japan

    PRESS RELEASE

    Takeda Puts Up to $1.3B for Keros’ Blood Cancer Anemia Drug

    PRESS RELEASE

    Keros Signs Global License Deal with Takeda for Elritercept

    GLOBENEWSWIRE

    Alloy Partners with Takeda on iPSC-Derived Cell Therapies

    CONTRACTPHARMA

    Takeda axes Huntington’s pact, freeing Wave to pursue partners

    FIERCE BIOTECH

    Tempus Expands Takeda Collaboration In Oncology Research

    BUSINESSWIRE

    Takeda`s vaccine `Qdenga`, a promising solution for dengue control in India

    ECONOMICTIMES

    HilleVax stock sink 80% as Norovirus Vaccine flunks phase 2 trial in infants

    FIERCE BIOTECH

    Silence breaks phase 1 data on blood disorder prospect

    FIERCE BIOTECH

    Takeda Presents Late-Breaking Data on Mezagitamab for Thrombocytopenia

    BUSINESSWIRE

    Takeda and Pfizer announce results from Positive Phase 3

    PRESS RELEASE

    Frontline ADCETRIS Combo Shows 4-Year Survival Benefit In Hodgkin Lymphoma

    BUSINESSWIRE

    WHO clears Takeda`s dengue vaccine

    REUTERS

    Nabla Bio secures $26m in Series A funding round

    PHARMACEUTICAL TECHNOLOGY

    Beacon, Takeda Collaborate On Neurobiomarkers For Sleep Disorders

    GLOBENEWSWIRE

    Protagonist Announces Closing of Worldwide Rusfertide License

    ACCESSWIRE

    AIC Offers Takeda’s GLASSIA and ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.